Skip to main content

Table 3 Multivariate analyses of factors affecting overall survival across BCLC stage

From: Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC

Variable Multivariable Cox regression
Total cohort BCLC 0/A BCLC B/C
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age, years 1.03 (0.72–1.48) 0.868 1.08 (0.61–1.93) 0.791 0.79 (0.49–1.29) 0.343
Male gender 0.86 (0.53–1.40) 0.541 1.10 (0.51–2.37) 0.803 0.85 (0.44–1.65) 0.626
Platelet count, × 109/l 1.62 (1.10–2.38) 0.014 1.90 (1.02–3.53) 0.043 1.26 (0.75–2.11) 0.383
Prothrombin time, sec 1.00 (0.89–1.12) 0.938 0.92 (0.76–1.11) 0.362 1.07 (0.92–1.25) 0.379
Serum AFP, ng/ml 1.09 (0.80–1.49) 0.594 1.22 (0.72–2.05) 0.457 0.92 (0.61–1.39) 0.677
Tumor size, cm 1.71 (1.21–2.44) 0.003 1.95 (1.15–3.32) 0.014 1.58 (0.95–2.64) 0.079
ALBI score 1.62 (1.18–2.22) 0.003 2.29 (1.39–3.78) 0.001 1.42 (0.91–2.20) 0.122
Major hepatectomy 1.33 (0.93–1.88) 0.115 1.02 (0.53–1.95) 0.965 1.33 (0.86–2.08) 0.201
MVI 2.10 (1.49–2.97) < 0.001 1.91 (1.13–3.01) 0.028 1.53 (0.89–2.83) 0.046
Differentiation grade 1.69 (1.24–2.30) 0.001 1.77 (1.08–2.89) 0.024 2.03 (1.28–3.23) 0.003
MELD score 0.98 (0.90–1.08) 0.727 0.98 (0.84–1.15) 0.803 1.00 (0.88–1.14) 0.989
  1. HR hazard ratio, CI confidence interval, BCLC Barcelona Clinic Liver Cancer, AFP α-fetoprotein, ALBI albumin-bilirubin, MVI microvascular invasion, MELD model for end-stage liver disease